Rahmani Parisa, Ghouran-Orimi Azin, Motamed Farzaneh, Moradzadeh Alireza
Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iran university of Medical Sciences, Tehran, Iran.
Clin Exp Pediatr. 2020 Dec;63(12):485-490. doi: 10.3345/cep.2019.01613. Epub 2020 Jul 21.
Recurrent abdominal pain (RAP) is one of the frequent complaints in general practice, particularly in pediatrics and is among the common cause of referral to gastroenterology clinics.
This study is designed to investigate the effects of probiotics for the treatment of RAP and desired therapeutic outcomes.
One hundred twenty-five children with the diagnosis of RAP according to Rome III criteria for irritable bowel syndrome (IBS), functional abdominal pain (FAP), functional dyspepsia (FD), and abdominal migraine (AM), were enrolled in this double-blind randomized controlled trial.
Sixty-five subjects received probiotics, and others received placebo treatment for 4 weeks. Lactobacillus reuteri was therapeutically effective in 32 patients compared to 8 patients, responding to the placebo treatment. Compared to baseline, all pain-related variables showed a significant reduction for the IBS and FD at the end of the 4th week. However, it did not respond well in FAP and AM groups. Pain-related outcomes such as, frequency of the pain, severity, and duration of the pain were decreased following the probiotic treatment. No therapeutic response was seen in AM group after the administration of probiotics. L. reuteri significantly led to pain relief in the overall population, and also in FAP, FD, and IBS subgroups.
L. reuteri probiotics are likely to lead to RAP relief and can be recommended for the treatment of functional gastrointestinal disorders.
反复腹痛（RAP）是全科医疗中常见的主诉之一，尤其是在儿科，也是转诊至胃肠病诊所的常见原因之一。
本研究旨在调查益生菌治疗RAP的效果及预期治疗结果。
根据罗马III标准诊断为肠易激综合征（IBS）、功能性腹痛（FAP）、功能性消化不良（FD）和腹型偏头痛（AM）的125名儿童纳入了这项双盲随机对照试验。
65名受试者接受益生菌治疗，其余受试者接受安慰剂治疗4周。与8名对安慰剂治疗有反应的患者相比，32名患者服用罗伊氏乳杆菌治疗有效。与基线相比，第4周结束时，IBS和FD组所有与疼痛相关的变量均显著降低。然而，FAP和AM组反应不佳。益生菌治疗后，疼痛频率、严重程度和持续时间等与疼痛相关的结果有所下降。服用益生菌后，AM组未见治疗反应。罗伊氏乳杆菌在总体人群以及FAP、FD和IBS亚组中均显著缓解了疼痛。
罗伊氏乳杆菌益生菌可能会缓解RAP，可推荐用于治疗功能性胃肠疾病。
